RE:RE:RE:RE:RE:RE:RE:Type C Meeting TimingsType C FDA meetings are a "catch-all" category and include any meeting concerning the development and review of a product that does not fall within the scope of Types A or B. The FDA notes that it will attempt to schedule all Type C meetings within 75 days of receiving the written meeting request.
When requesting a Type C meeting, Sponsors can request a written response to their questions rather than an in-person meeting, videoconference, or teleconference. A Sponsor may request a face-to-face meeting, but the FDA may decide that only a written response is necessary.
The meeting package for a Type C meeting is due 47 days before the scheduled meeting date. For Type C meetings that are requested as early consultations on the use of a new surrogate endpoint to be used as the primary basis for product approval in a proposed context of use, the meeting package is due at the time of the meeting request.
https://www.fda.gov/vaccines-blood-biologics/cellular-gene-therapy-products/otp-type-c-meetings